TY - JOUR
T1 - Radioterapia neoadiuvante associata ad oxaliplatino e 5-fluorouracile in pazienti affetti da tumore rettale localmente avanzato
T2 - l'esperienza di un singolo centro
AU - Greto, D.
AU - Paiar, F.
AU - Saieva, C.
AU - Galardi, A.
AU - Mangoni, M.
AU - Livi, L.
AU - Agresti, B.
AU - Franceschini, D.
AU - Bonomo, P.
AU - Scotti, V.
AU - Detti, B.
AU - Tonelli, F.
AU - Valeri, A.
AU - Messerini, L.
AU - Biti, G.
PY - 2013/6
Y1 - 2013/6
N2 - Purpose: The aim of this study was to evaluate the rate of pathological response (PR), disease control and safety of neoadjuvant chemotherapy using oxaliplatin (OX) and 5-fluorouracil (5-FU) with concurrent radiotherapy for treating locally advanced rectal cancer. Materials and methods: Between November 2002 and December 2010, 90 patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy (CRT) were retrospectively analysed. All patients underwent preoperative radiotherapy (45 Gy in 1.8-Gy fractions) with concurrent OX (80 mg/m2 i.v., day 1) and a 120-h continuous infusion of 5-FU (1,000 mg/m2 per day). Surgery was performed within 6 weeks after completion of CRT treatment. Results: Complete pathological response was obtained in six patients (6.7%), and 39 (43.3%) had their disease downstaged. The median follow-up period was 4.7 years (6 months to 9 years). Local recurrence occurred in two patients (2.2%), one of whom developed also liver metastases. Distant metastases not associated with local relapse occurred in 23 (25.6%) patients. Overall (OS) and disease-free (DFS) survival were 62.9% and 52.8%, respectively. CRT was well tolerated, with only one grade 3 (1.2%) haematological toxicity (neutropaenia). Conclusions: Neoadjuvant systemic chemotherapy based on OX and 5-UC associated with radiotherapy is well tolerated, with good results in terms of pathological response, disease control and survival, in rectal cancer patients.
AB - Purpose: The aim of this study was to evaluate the rate of pathological response (PR), disease control and safety of neoadjuvant chemotherapy using oxaliplatin (OX) and 5-fluorouracil (5-FU) with concurrent radiotherapy for treating locally advanced rectal cancer. Materials and methods: Between November 2002 and December 2010, 90 patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy (CRT) were retrospectively analysed. All patients underwent preoperative radiotherapy (45 Gy in 1.8-Gy fractions) with concurrent OX (80 mg/m2 i.v., day 1) and a 120-h continuous infusion of 5-FU (1,000 mg/m2 per day). Surgery was performed within 6 weeks after completion of CRT treatment. Results: Complete pathological response was obtained in six patients (6.7%), and 39 (43.3%) had their disease downstaged. The median follow-up period was 4.7 years (6 months to 9 years). Local recurrence occurred in two patients (2.2%), one of whom developed also liver metastases. Distant metastases not associated with local relapse occurred in 23 (25.6%) patients. Overall (OS) and disease-free (DFS) survival were 62.9% and 52.8%, respectively. CRT was well tolerated, with only one grade 3 (1.2%) haematological toxicity (neutropaenia). Conclusions: Neoadjuvant systemic chemotherapy based on OX and 5-UC associated with radiotherapy is well tolerated, with good results in terms of pathological response, disease control and survival, in rectal cancer patients.
KW - 5-Fluorouracil
KW - Chemoradiotherapy
KW - Locally advanced rectal cancer
KW - Oxaliplatin
UR - http://www.scopus.com/inward/record.url?scp=84879419226&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879419226&partnerID=8YFLogxK
U2 - 10.1007/s11547-012-0909-4
DO - 10.1007/s11547-012-0909-4
M3 - Articolo
C2 - 23358814
AN - SCOPUS:84879419226
VL - 118
SP - 570
EP - 582
JO - Radiologia Medica
JF - Radiologia Medica
SN - 0033-8362
IS - 4
ER -